Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-02-28
2010-02-23
Saunders, David A. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S144100, C424S145100, C424S177100, C530S387100, C530S387300, C530S388100, C530S388250, C530S390500
Reexamination Certificate
active
07666413
ABSTRACT:
The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
REFERENCES:
patent: 4093606 (1978-06-01), Coval
patent: 4374763 (1983-02-01), Takagi
patent: 4499073 (1985-02-01), Tenold
patent: 4877608 (1989-10-01), Lee et al.
patent: 4940782 (1990-07-01), Rup et al.
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5215743 (1993-06-01), Singh et al.
patent: 5252480 (1993-10-01), Yokota et al.
patent: 5262296 (1993-11-01), Ogawa et al.
patent: 5328694 (1994-07-01), Schwinn
patent: 5399670 (1995-03-01), Bhattacharya et al.
patent: 5580856 (1996-12-01), Prestrelski et al.
patent: 5608038 (1997-03-01), Eibl et al.
patent: 5612315 (1997-03-01), Pikal et al.
patent: 5849700 (1998-12-01), Sorenson et al.
patent: 5871736 (1999-02-01), Bruegger et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6037453 (2000-03-01), Jardieu et al.
patent: 6096872 (2000-08-01), Van Holten et al.
patent: 6172213 (2001-01-01), Lowman et al.
patent: 6252055 (2001-06-01), Relton
patent: 6267958 (2001-07-01), Andya et al.
patent: 6290957 (2001-09-01), Lowman et al.
patent: 6329509 (2001-12-01), Jardieu et al.
patent: 6440426 (2002-08-01), Wheeler et al.
patent: 6541606 (2003-04-01), Margolin et al.
patent: 6682735 (2004-01-01), Lowman et al.
patent: 6685939 (2004-02-01), Jardieu et al.
patent: 6685940 (2004-02-01), Andya et al.
patent: 6699472 (2004-03-01), Jardieu et al.
patent: 6723833 (2004-04-01), Lowman et al.
patent: 6875432 (2005-04-01), Liu et al.
patent: 7157085 (2007-01-01), Lowman et al.
patent: 2002/0045571 (2002-04-01), Liu et al.
patent: 2003/0092607 (2003-05-01), Carpenter et al.
patent: 2003/0113316 (2003-06-01), Kaisheva et al.
patent: 2003/0138417 (2003-07-01), Kaisheva et al.
patent: 2004/0019243 (2004-01-01), Nightingale et al.
patent: 2004/0191243 (2004-09-01), Chen et al.
patent: 2004/0197324 (2004-10-01), Liu et al.
patent: 2005/0158303 (2005-07-01), Liu et al.
patent: 2006/0051347 (2006-03-01), Winter
patent: 2006/0127395 (2006-06-01), Arvinte et al.
patent: 2007/0053900 (2007-03-01), Liu et al.
patent: 2007/0086995 (2007-04-01), Liu et al.
patent: 2007/0116700 (2007-05-01), Liu et al.
patent: 2138853 (1995-06-01), None
patent: 0 117 060 (1984-08-01), None
patent: 0 117 060 (1984-08-01), None
patent: 0 303 746 (1989-02-01), None
patent: 0 303 746 (1989-02-01), None
patent: 0 303 746 (1989-02-01), None
patent: 0 391 444 (1990-10-01), None
patent: 0 391 444 (1990-10-01), None
patent: 0 531 539 (1993-03-01), None
patent: 0 531 539 (1993-03-01), None
patent: 0 597 101 (1994-05-01), None
patent: 0 597 101 (1994-05-01), None
patent: 0 767 497 (1997-08-01), None
patent: 0 767 497 (1997-08-01), None
patent: 0 641 067 (1998-05-01), None
patent: 0 641 067 (1998-05-01), None
patent: 0 909 564 (1999-04-01), None
patent: 0 909 564 (1999-04-01), None
patent: 1 197 221 (2002-04-01), None
patent: 1 197 221 (2002-04-01), None
patent: 1 325 751 (2003-07-01), None
patent: 7-206709 (1995-08-01), None
patent: WO-89/11297 (1989-11-01), None
patent: WO 92/17207 (1992-10-01), None
patent: WO 93/04173 (1993-03-01), None
patent: WO-93/05799 (1993-04-01), None
patent: WO-96/20202 (1996-07-01), None
patent: WO 97/04801 (1997-02-01), None
patent: WO-97/26909 (1997-07-01), None
patent: WO-97/45140 (1997-12-01), None
patent: WO 99/01556 (1999-01-01), None
patent: WO-00/15260 (2000-03-01), None
patent: WO-02/30464 (2002-04-01), None
patent: WO-02/072636 (2002-09-01), None
patent: WO-02/072636 (2002-09-01), None
patent: WO-02/096457 (2002-12-01), None
patent: WO-02/096457 (2002-12-01), None
Mahler et al, Biological Chemistry, Harper & Row, 1966. Table 2.1.
Hudson et al, Practical Immunology, Second Edition, Blackwell Scientific Publications, 1980, p. 336.
Jones, A., “Analysis of Polypeptides and Proteins.”Adv. Drug Delivery Rev. (10)29-90 (1993).
Presta et al., “Humanization of an Antibody Directed Against IgE”J. Immunol. 151(5):2623-2632 (Sep. 1, 1993).
White et al.Principles of Biochemistry, 3rd edition, McGraw-Hill company pp. 540 (1964).
Zietkiewicz et al., “In Vivo Studies on the Action on the Tissue of the Osmolality of Parenterally Administered Drugs.”Grzyby Drozdzopodobne.(English Translation Attached) 23:869-870 (1971).
Bo Holma et al., “pH- and protein-dependent buffer capacity and viscosity of respiratory mucus, their interrelationships and influence on health”The Science of the Total Environment84:71 - 82 (1989).
Jacques Loeb, “Donnan equilibrium and the physical properties of proteins, III. Viscosity”The Journal of General Physiologypp. 827-841 (1921).
Jacques Loeb, “Donnan equilibrium and the physical properties of proteins, IV, Viscosity (continued)”The Journal of General Physiologypp. 73-95 (1921).
Jorge R. Wagner, et al., “Effect of physical and chemical factors on rheological behavior of commercial soy protein isolates: protein concentration, water imbibing capacity, salt addition, and thermal treatment”J. Agric. Food Chem, 40:1930 - 1937 (1992).
Schneider, et al., “Some viscosity characteristics of faba bean protein isolats within a pH range relevant for foods”Die Nahrunq34:735 - 745 (1990).
Yoh-Ichi Kinekawa, et al., “Effects of salts on the properties of sols and gels prepared from whey protein isolate and process whey protein”Journal of Dairy Science81(6):1532 - 1544 (1998).
International Search Report mailed on Jun. 19, 2002, for PCT Application No. PCT/US01/42487, filed on Oct. 4, 2001, two pages.
Iwanaga, S. (1978). “1-2-1 Separation Method Making Use of Solubility,”New Lectures on Experimental Chemistry20(Biochemistry 1):14-26, Japanese Language, (English Translation, 16 pages).
Milgrom, H. et al. (Dec. 23, 1999). “Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody. rhuMAb-E25 Study Group,”The New England Journal of Medicine341(26):1966-1973.
U.S. Appl. No. 12/197,005, filed Aug. 22, 2008, by Liu et al. (copy not attached).
Haecker, G. et al. (1994). “Proliferative and Cytolytic Responses of Human yδ T Cells Display a Distinct Specificity Pattern,”Immunology81:564-566.
Xu, X. et al. (1995). “Expression of Functional Insulin-Like Growth Factor-1 Receptor on Lymphoid Cell Subsets of Rats,”Immunology85:394-399.
Corne, J. et al. (Mar. 1997). “The Effect of Intravenous Administration of a Chimeric Anti-IgE Antibody on Serum IgE Levels in Atopic Subjects: Efficacy, Safety, and Pharmacokinetics,”J. Clin. Invest. 99(5):879-887.
Bam N. B. et al, (1995), “Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique,”Pharmaceutical Research12:2-11.
Carpenter, J.F. et al. (1997), “Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice,” Pharmaceutical Research 14(8):969-975.
Casolaro, V. et al. (1993). “Release from Human Basophils and Mast Cells”J. of Pharmacology and, Experimental Therapeutics267(3) :1375-1385.
Cleland, J.L. et al. (1993). “The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation”Critical Reviews in Therapeutic Drug Carrier Systems10(4):307-377.
Cleland, J.L. et al. (1995). “Development of Stable Protein Formulations for Microencapsulation in Biodegradable Polymers,”Proceed, Intern, Symp. Control, Rel. Bioact. Mater, 22:514-515.
Doutrelepont, J.M. et al. (1991). “Hyper IgE in Stimulatory Graft-versus-Hot Disease: Role of Interleukin-4,”Clin. Exp. lmmunol. 83:133-136.
Draber, P. et al. (1995). “Stability of Monoclonal IgM Antibodies Freeze-Dried in the Presence of Trehalose,”Journal of Immunological Methods18(1):37-43.
Liu, J. et al. (Sep. 2005). “Reversible Self-Association Increases the Viscosity of a Concentrated Monoclonal Ant
Liu Jun
Shire Steven J.
Genetech, Inc.
Morrison & Foerster / LLP
Novartis AG
Saunders David A.
LandOfFree
Method of reducing viscosity of high concentration protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing viscosity of high concentration protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing viscosity of high concentration protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4164720